GE HealthCare Expands Collaboration with DeepHealth to Advance AI Mammography Tools
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy GEHC?
GE HealthCare (GEHC) announced an expanded collaboration with DeepHealth, a player in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The announcement coincides with the Society of Breast Imaging Annual Symposium, where GE HealthCare will showcase its latest advancements in breast imaging and women's health. "At GE HealthCare, we're advancing women's health through precision care built around the unique needs of women and enhanced by the power of AI," said Jyoti Gupta, PhD, President and CEO, Women's Health and X-ray at GE HealthCare. "By integrating Breast Suite AI with our Pristina Via(TM) mammography system, we're helping clinicians detect breast cancer early with greater confidence. These innovations move us closer towards truly personalized prevention and care for women."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 74.660
Low
80.00
Averages
92.25
High
105.00
Current: 74.660
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Structural Shift in U.S. Heart Care Market
- Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
- AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
- New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
- Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
See More
Exxon Mobil Gains from Middle East War Impacting Helium Supply
- Market Opportunity: The ongoing Middle East war has tightened global helium supply, with UBS analysts noting that Exxon Mobil stands to benefit as a net beneficiary of helium market conditions, particularly as Qatar's production is disrupted.
- Production Capacity: Exxon's LaBarge facility in Wyoming is capable of producing approximately 1.4 billion cubic feet of Grade A helium annually, remaining unaffected by Middle Eastern events, and is expected to play a significant role in helium supply for the next eight decades.
- Price Surge: Spot helium prices have soared to $1,000-$1,200 per thousand cubic feet due to the war, up from about $500 under older contracts, with UBS estimating that every $100 increase in prices could add $119 million to Exxon's EBITDA.
- Investment Rating: UBS reiterated a buy rating for Exxon Mobil with a 12-month price target of $171, implying about 5% upside from Monday's close of $163.37, reflecting positive market sentiment regarding the company's growth prospects.
See More
Profitable Companies May Not Last
- Caution on GE Healthcare: GE Healthcare's annual revenue growth of only 2.7% over the past two years significantly lags behind other healthcare firms, indicating core business struggles that may necessitate acquisitions for growth stimulation, with a current share price of $70.42 and a forward P/E of 14.2x.
- Northern Trust's Slow Growth: Northern Trust has experienced muted annual revenue growth of 5.8% over the last five years, with its EPS growth of 9.3% falling short of peer averages, trading at $142.24 per share and a forward P/E of 13x, reflecting demand lagging behind financial performance.
- Doximity's Strong Performance: Doximity boasts an impressive annual revenue growth of 29.3% over the past five years, showcasing market share gains, and its user-friendly software allows clients to quickly ramp up spending, with a current stock price of $22.94 and a forward price-to-sales ratio of 6.7x, indicating robust cash flow and investment flexibility.
- High-Quality Stocks in Focus: While many profitable companies exist, not all are poised for sustained growth; analysis reveals that only a select few can maintain high-quality growth across various market conditions, prompting investors to focus on these potential winners.
See More
Analysis of GEHC Dividend Predictions and Stock Performance
- Dividend Yield Analysis: GEHC's estimated annualized dividend yield stands at 0.20%, and while dividends are not always predictable, historical data can aid in assessing the likelihood of future dividend sustainability, impacting investor return expectations.
- Price Volatility Range: The 52-week low for GEHC is $57.65 per share, with a high of $89.77, while the latest trade price is $71.45, indicating that the stock is within its volatility range, which may influence investor buying decisions.
- ETF Holdings Overview: According to ETF Finder, GEHC comprises 10.07% of the AGF U.S. Market Neutral Anti-Beta Fund (BTAL), which is trading down approximately 1.3% on the day, reflecting overall market sentiment towards GEHC.
- Intraday Trading Performance: In Wednesday trading, GEHC shares are up about 0.7%, indicating a short-term bullish sentiment in the market, which may attract more investor attention.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
Structural Shift in U.S. Heart Care Market
- Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
- AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
- New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
- Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
See More
Exxon Mobil Gains from Middle East War Impacting Helium Supply
- Market Opportunity: The ongoing Middle East war has tightened global helium supply, with UBS analysts noting that Exxon Mobil stands to benefit as a net beneficiary of helium market conditions, particularly as Qatar's production is disrupted.
- Production Capacity: Exxon's LaBarge facility in Wyoming is capable of producing approximately 1.4 billion cubic feet of Grade A helium annually, remaining unaffected by Middle Eastern events, and is expected to play a significant role in helium supply for the next eight decades.
- Price Surge: Spot helium prices have soared to $1,000-$1,200 per thousand cubic feet due to the war, up from about $500 under older contracts, with UBS estimating that every $100 increase in prices could add $119 million to Exxon's EBITDA.
- Investment Rating: UBS reiterated a buy rating for Exxon Mobil with a 12-month price target of $171, implying about 5% upside from Monday's close of $163.37, reflecting positive market sentiment regarding the company's growth prospects.
See More
Profitable Companies May Not Last
- Caution on GE Healthcare: GE Healthcare's annual revenue growth of only 2.7% over the past two years significantly lags behind other healthcare firms, indicating core business struggles that may necessitate acquisitions for growth stimulation, with a current share price of $70.42 and a forward P/E of 14.2x.
- Northern Trust's Slow Growth: Northern Trust has experienced muted annual revenue growth of 5.8% over the last five years, with its EPS growth of 9.3% falling short of peer averages, trading at $142.24 per share and a forward P/E of 13x, reflecting demand lagging behind financial performance.
- Doximity's Strong Performance: Doximity boasts an impressive annual revenue growth of 29.3% over the past five years, showcasing market share gains, and its user-friendly software allows clients to quickly ramp up spending, with a current stock price of $22.94 and a forward price-to-sales ratio of 6.7x, indicating robust cash flow and investment flexibility.
- High-Quality Stocks in Focus: While many profitable companies exist, not all are poised for sustained growth; analysis reveals that only a select few can maintain high-quality growth across various market conditions, prompting investors to focus on these potential winners.
See More
Analysis of GEHC Dividend Predictions and Stock Performance
- Dividend Yield Analysis: GEHC's estimated annualized dividend yield stands at 0.20%, and while dividends are not always predictable, historical data can aid in assessing the likelihood of future dividend sustainability, impacting investor return expectations.
- Price Volatility Range: The 52-week low for GEHC is $57.65 per share, with a high of $89.77, while the latest trade price is $71.45, indicating that the stock is within its volatility range, which may influence investor buying decisions.
- ETF Holdings Overview: According to ETF Finder, GEHC comprises 10.07% of the AGF U.S. Market Neutral Anti-Beta Fund (BTAL), which is trading down approximately 1.3% on the day, reflecting overall market sentiment towards GEHC.
- Intraday Trading Performance: In Wednesday trading, GEHC shares are up about 0.7%, indicating a short-term bullish sentiment in the market, which may attract more investor attention.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
